Infectious Disease

The Infectious Disease theme encompasses companies developing prevention, detection, and treatment solutions for viral, bacterial, and emerging pathogens. Core tracks include vaccines and platform technologies (mRNA, viral vectors), anti-infective therapeutics and monoclonal antibodies, rapid and molecular diagnostics, genomic surveillance and biosecurity, hospital infection control and sterilization, and public-health data analytics and distribution, spanning the value chain from research and clinical trials to manufacturing, point-of-care testing, and outbreak response.The sector's total market cap is 2345.21 billion USD, with a 24h change of +0.60%. Among 16 constituents, 14 are up (87.50%) and 2 are down (12.50%). The top gainer is Moderna, Inc. (MRNA), with a 24h increase of +2.88%.Firm breadth, tight leadership; favor large caps. Short-term trade momentum; add on trial and approval catalysts.